Leqvio effective in LDL-C reduction over four years

Novartis (NOVN: VX) has presented new data on Leqvio (inclisiran), an siRNA product approved in primary hyperlipidemia as an adjunct to diet and maximally tolerated statin therapy to reduce low-density lipoprotein cholesterol (LDL-C).

The Swiss pharma giant has announced results from the Phase II open-label extension ORION-3 trial, which showed that Leqvio provides effective LDL-C reduction over a four-year period in either atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalent, and elevated LDL-C despite maximally tolerated statin therapy.

"A large, high-risk population in the USA"